Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Polyclonal Breast Cancer Metastases Are Generated by Clusters of Migrating Cells

By LabMedica International staff writers
Posted on 14 Feb 2016
A recent study confirmed that, contrary to conventional wisdom, cancer metastasis usually depends on the release of clusters of cells rather than single cells from the primary tumor.

Conventional models of cancer progression propose that single cells leave the primary tumor, enter the circulation, and seed metastases based on the clonal type of that cell. More...
However, metastases can contain multiple clones, raising the question of how polyclonal metastases are formed.

To answer this question investigators at Johns Hopkins University (Baltimore, MD, USA) used multicolor lineage tracing to follow red or green tagged cells as they escaped from a primary tumor (in culture or in a mouse model) to form daughter tumors.

They reported in the February 1, 2016, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that polyclonal seeding by cell clusters was the most frequent mechanism in a common mouse model of breast cancer, accounting for more than 90% of metastases. They directly observed multicolored tumor cell clusters across major stages of metastasis, including collective invasion, local dissemination, intravascular emboli, circulating tumor cell clusters, and micrometastases.

Experimentally aggregating tumor cells into clusters induced a greater than 15-fold increase in colony formation in three-dimensional in vitro gel culture and a greater than 100-fold increase in metastasis formation in a mouse model.

The investigators found that the most invasive clones frequently expressed the epithelial cytoskeletal protein, keratin 14 (K14), which regulated cell-cell adhesion, cell-matrix adhesion, and immune evasion. When K14 expression was blocked, there was a dramatic reduction in formation of distant metastases combined with disrupted expression of multiple metastasis effectors.

“We found that cancer cells do two things to increase their chances of forming a new metastasis,” said senior author Dr. Andrew Ewald, associate professor of cell biology at Johns Hopkins University. “They turn on a molecular program that helps them travel through a diverse set of environments within the body, and they travel in groups.”

“Because most chemotherapeutic drugs target proliferating cells, metastasizing cells would not be killed by them, leaving patients vulnerable to new tumors,” said Dr. Ewald. “Our discoveries add to knowledge that could help overcome that vulnerability. We found that the activity of dozens of genes differs between proliferating and metastasizing cells. Since many of those genes encode cell surface proteins, we hope these findings might eventually be used to develop new drugs that target metastasizing cells.”

Related Links:
Johns Hopkins University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.